AM-111 in the Treatment of Acute Inner Ear Hearing Loss (HEALOS)

This study is currently recruiting participants.

See

Contacts and Locations

Verified January 2017 by Auris Medical, Inc. ( Auris Medical AG )

Sponsor:

Information provided by (Responsible Party):

Auris Medical, Inc. ( Auris Medical AG )

ClinicalTrials.gov Identifier:

NCT02561091

First received: September 23, 2015

Last updated: January 18, 2017

Last verified: January 2017

History of Changes

Purpose

The purpose of this research study is to test the effectiveness and safety of the study drug, AM-111. AM-111 is tested for the treatment of sudden sensorineural hearing loss where the cause is unknown.

Condition	Intervention	Phase
Hearing Loss	Other: Placebo Drug: AM-111 0.4 mg/ml Drug: AM-111 0.8 mg/ml	Phase 3


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	Efficacy and Safety of AM-111 in the Treatment of Acute Inner Ear Hearing Loss

Resource links provided by NLM:

Genetics Home Reference related topics: nonsyndromic hearing loss

MedlinePlus related topics: Hearing Disorders and Deafness

U.S. FDA Resources

Further study details as provided by Auris Medical, Inc. ( Auris Medical AG ):

Primary Outcome Measures:

Pure tone average (PTA; average of the hearing threshold of three contiguous most affected hearing frequencies in dB) [ Time Frame: Day 28 ]
Assessment with pure tone audiometry/ Measurement at 8 frequencies/ Final outcome is the absolute improvement in PTA from D0 to D28


Estimated Enrollment:	255
Study Start Date:	November 2015
Estimated Study Completion Date:	September 2017
Estimated Primary Completion Date:	September 2017 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Placebo Comparator: Placebo Placebo gel for intratympanic use	Other: Placebo
Experimental: AM-111 0.4 mg/ml AM-111 gel for intratympanic use (0.4 mg/ml AM-111)	Drug: AM-111 0.4 mg/ml
Experimental: AM-111 0.8 mg/ml AM-111 gel for intratympanic use (0.8 mg/ml AM-111)	Drug: AM-111 0.8 mg/ml

Detailed Description:

This phase III study is assessing the drug's safety and is aiming to demonstrate efficacy of intratympanic AM-111 injections in the treatment of severe to profound idiopathic sudden sensorineural hearing loss (ISSNHL). The active pharmaceutical ingredient of AM-111 is the JNK inhibitor (D-JNKI-1), a synthetic peptide consisting of 31 D-amino acids, which acts as a c-Jun N-terminal kinase (JNK) ligand.

Eligibility


Ages Eligible for Study:	18 Years to 65 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Unilateral ISSNHL with onset within 72 hours prior to study treatment;
Mean hearing threshold of equal to or worse than (≥) 60 dB averaged across the 3 most affected contiguous air conduction audiometric pure tone frequencies ("pure tone average", PTA);*
Mean hearing loss of equal to or worse than (≥) 40 dB averaged across the air conducted PTA frequencies compared with the unaffected contralateral ear or reference values from a pre-existing audiogram or ISO 7029;2000 norm values in case of asymmetric hearing prior to the ISSNHL incident;
Age ≥ 18 and ≤ 65 years on the day of screening;

Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

Bilateral ISSNHL;
Acute hearing loss from noise trauma, barotrauma or head trauma;
History of autoimmune hearing loss, radiation-induced hearing loss, endolymphatic hydrops or Menière's disease in the affected ear;
History of chronic inflammatory or suppurative ear disease or cholesteatoma in the affected ear;
History of acoustic neuroma or other retrocochlear damage in the affected ear;
History of otosclerosis in the affected ear;
Suspected perilymph fistula or membrane rupture in the affected ear;
Congenital hearing loss;
History of ISSNHL in the past 2 years;
Otitis media or otitis externa that is ongoing or ended within 7 days prior to study treatment;

Other protocol-defined exclusion criteria may apply.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02561091

Contacts


Contact: Auris Medical	+41 61 201 13 50

Locations


Bulgaria
Please check link to study webpage below for more study sites	Recruiting
Sofia, Bulgaria

Sponsors and Collaborators

Auris Medical AG

More Information

Additional Information:

Study webpage with information about study and participating sites This link exits the ClinicalTrials.gov site


Responsible Party:	Auris Medical AG
ClinicalTrials.gov Identifier:	NCT02561091 History of Changes
Other Study ID Numbers:	AM-111-CL-13-01
Study First Received:	September 23, 2015
Last Updated:	January 18, 2017

Keywords provided by Auris Medical, Inc. ( Auris Medical AG ):


Deafness Hearing Loss, Sensorineural Ear Diseases Hearing Disorders Otorhinolaryngologic Diseases	Sensation Disorders Signs and Symptoms Hearing and Speech impairment Hearing Loss, Unilateral

Additional relevant MeSH terms:


Hearing Loss Deafness Hearing Loss, Sensorineural Hearing Disorders Ear Diseases	Otorhinolaryngologic Diseases Sensation Disorders Neurologic Manifestations Nervous System Diseases Signs and Symptoms

ClinicalTrials.gov processed this record on August 18, 2017

To Top